(4-(氨基甲基)苯基)(吗啉代)甲酮 | 923138-47-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: (4-(氨基甲基)苯基)(吗啉代)甲酮
• 英文名称: (4-(aminomethyl)phenyl)(morpholino)methanone
• 英文别名: 4-(Morpholinocarbonyl)benzylamine；[4-(aminomethyl)phenyl]-morpholin-4-ylmethanone
• CAS: 923138-47-0
• 化学式: C₁₂H₁₆N₂O₂
• mdl: MFCD08444572
• 分子量: 220.271
• InChiKey: HNCQITIOVQUUQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4-(氨基甲基)苯基)(吗啉代)甲酮 、 9-[5-S-(2-acetamidoethyl)-2,3-di-O-acetyl-5-thio-β-D-ribofuranosyl]-6-fluoropurine 在 三乙胺 作用下， 以 甲醇 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  Improved Syntheses of 5′-S-(2-Aminoethyl)-6-N-(4-nitrobenzyl)-5′-thioadenosine (SAENTA), Analogues, and Fluorescent Probe Conjugates: Analysis of Cell-Surface Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels for Prediction of the Antitumor Efficacy of Gemcitabine

  摘要：

  5'-S-(2-Aminoethyl)-6-N-(4-nitrobenzyl)-5'-thioadenosine (SAENTA), 5'-S-(2-acetamidoethyl)-6-N-[(4-substituted)benzyl]-5'-thioadenosine analogues, 5'-S-[2-(6-aminohexanamido)lethyl-6-N-(4-nitrobenzyl)-5'-thioadenosine (SAHENTA), and related compounds were synthesized by S(N)Ar displacement of fluoride from 6-fluoropurine intermediates with 4-(substituted)benzylamines. Conjugation of the pendant amino groups of SAENTA and SAHENTA with fluorescein-5-yl isothiocyanate (FITC) gave fluorescent probes that bound at nanomolar concentrations specifically to human equilibrative nucleoside transporter 1 (hENT1) produced in recombinant form in model expression systems and in native form in cancer cell lines. Transporter binding effects were studied and the ability of the probes to predict the potential antitumor efficacy of 2'-deoxy-2',2'-difluorocylidine (gemcitabine) was demonstrated.

  DOI：

  10.1021/jm100432w
• 作为产物：
  描述：

  4-[(叔丁氧羰基氨基)甲基]苯甲酸 在 盐酸 、 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 4.17h， 生成 (4-(氨基甲基)苯基)(吗啉代)甲酮
  参考文献：
  名称：

  KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

  摘要：

  Provided herein are compounds and compositions useful in inhibiting a receptor tyrosine kinase, KIT.　The compounds and compositions provided herein are useful for the prevention or treatment of one or more KIT mediated diseases or conditions (e.g., cancers, autoimmune diseases, allergic diseases, inflammatory diseases, fibrosis, metabolic disorders, and neurodegenerative diseases).

  公开号：

  WO2024117179A1

文献信息

• Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
  申请人：NUEVOLUTION A/S

  公开号：US10689383B2

  公开（公告）日：2020-06-23

  Disclosed are compounds of Formula I, which are active toward nuclear receptors such as nuclear retinoic acid receptor-related orphan receptors (RORs), pharmaceutical compositions containing the compounds of Formula I, and methods of treating inflammatory, metabolic, oncologic and autoimmune diseases or disorders using the of the compounds Formula I in therapy.

  公开了对核受体（如核视黄酸受体相关孤儿受体（RORs））具有活性的式 I 化合物、含有式 I 化合物的药物组合物，以及使用式 I 化合物治疗炎症、代谢、肿瘤和自身免疫性疾病或紊乱的方法。
• OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES
  申请人：NUEVOLUTION A/S

  公开号：US20170327503A1

  公开（公告）日：2017-11-16

  Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.